ATE364698T1 - Neues, physiologisch aktives peptid und dessen verwendung - Google Patents
Neues, physiologisch aktives peptid und dessen verwendungInfo
- Publication number
- ATE364698T1 ATE364698T1 AT01951893T AT01951893T ATE364698T1 AT E364698 T1 ATE364698 T1 AT E364698T1 AT 01951893 T AT01951893 T AT 01951893T AT 01951893 T AT01951893 T AT 01951893T AT E364698 T1 ATE364698 T1 AT E364698T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- compound
- salt
- screening
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217442 | 2000-07-18 | ||
| JP2001026779 | 2001-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364698T1 true ATE364698T1 (de) | 2007-07-15 |
Family
ID=26596235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01951893T ATE364698T1 (de) | 2000-07-18 | 2001-07-17 | Neues, physiologisch aktives peptid und dessen verwendung |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7045299B2 (de) |
| EP (1) | EP1302542B1 (de) |
| AT (1) | ATE364698T1 (de) |
| AU (1) | AU2001272735A1 (de) |
| DE (1) | DE60128916T2 (de) |
| WO (1) | WO2002006483A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223727B2 (en) * | 1998-04-09 | 2007-05-29 | Serono Genetics Institute S.A. | GSSP4 polynucleotides and polypeptides and uses thereof |
| CA2387711A1 (en) * | 1999-08-27 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Novel g protein-coupled receptor protein and dna thereof |
| US6485938B1 (en) * | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
| JP2004532609A (ja) | 2000-11-03 | 2004-10-28 | ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア | プロキネチシンポリペプチド、関連組成物および方法 |
| AU2002367629A1 (en) * | 2001-02-05 | 2003-10-08 | Bristol-Myers Squibb Company | A novel human g-protein coupled receptor, hgprbmy14, related to the orphan gpcr, gpr73 |
| WO2003066860A1 (fr) * | 2002-02-04 | 2003-08-14 | Takeda Chemical Industries, Ltd. | Inhibiteurs d'angiogenese |
| US7410956B2 (en) * | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
| CA2500587A1 (en) | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Screening and therapeutic methods relating to neurogenesis |
| WO2004031367A2 (en) * | 2002-10-07 | 2004-04-15 | Zymogenetics, Inc. | Uses of human zven proteins and polynucleotides |
| WO2004065419A1 (ja) * | 2003-01-22 | 2004-08-05 | Takeda Pharmaceutical Company Limited | 抗体およびその用途 |
| US20080219985A1 (en) * | 2005-09-13 | 2008-09-11 | Thompson Penny J | Prok2 antagonists and methods of use |
| JP2007121271A (ja) * | 2005-09-30 | 2007-05-17 | National Institute Of Advanced Industrial & Technology | ８−ヒドロキシ−２’−デオキシグアノシンの測定方法及び測定のための装置 |
| WO2008096905A1 (ja) | 2007-02-09 | 2008-08-14 | Tokyo Metropolitan Organization For Medical Research | 抗ｂｒａｋ（ｃｘｃｌ１４）ヒトモノクローナル抗体及びその用途 |
| JP5504513B2 (ja) * | 2008-02-19 | 2014-05-28 | 株式会社タニタ | カラム充填剤、これを用いたカラムおよび分離方法 |
| BR112015010691A2 (pt) | 2012-11-13 | 2017-08-22 | Regeneron Pharma | Anticorpo que se liga especificamente ao receptor de procineticina (prokr), seu uso no tratamento ou atenuação da dor e composição farmacêutica que o compreende |
| US9942187B2 (en) | 2014-03-10 | 2018-04-10 | Harry Leonard Perper | Alert for messages “stuck” in a message queue within a messaging application |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN112553229A (zh) | 2014-11-05 | 2021-03-26 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| EP3230441A4 (de) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur herstellung von scaav |
| WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics, Inc. | composições e métodos de tratamento da doença de huntington |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| RU2662944C1 (ru) * | 2017-02-17 | 2018-07-31 | Общество с ограниченной ответственностью "Группа развития "АПЕКС" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| WO2019173434A1 (en) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
| AU2019268330A1 (en) | 2018-05-15 | 2020-11-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
| EP3793686A1 (de) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Aav-serotypen zur gehirnspezifischen payload-übertragung |
| US20210254103A1 (en) | 2018-07-02 | 2021-08-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| MX2021000810A (es) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Sistemas y metodos para producir formulaciones de terapia genetica. |
| EP3856762A1 (de) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| EP3911410A1 (de) | 2019-01-18 | 2021-11-24 | Voyager Therapeutics, Inc. | Verfahren und systeme zur herstellung von aav-partikeln |
| US20220243225A1 (en) | 2019-04-29 | 2022-08-04 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4022070A1 (de) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Kontrollierte expression viraler proteine |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4301768A2 (de) | 2021-03-03 | 2024-01-10 | Voyager Therapeutics, Inc. | Kontrollierte expression von viralen proteinen |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CN120543373B (zh) * | 2025-07-29 | 2025-10-03 | 中国海洋大学 | 基于递归双流Mamba的海温补全方法及系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891720A (en) | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
| AU8555198A (en) | 1997-08-01 | 1999-02-22 | Genset | 5' ests for secreted proteins expressed in prostate |
| CA2328895A1 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2354685A1 (en) | 1998-12-10 | 2000-06-15 | Synaptic Pharmaceutical Corporation | Dna encoding a mammalian receptor (fb41a) and uses thereof |
| AU3386800A (en) * | 1999-03-01 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Secreted proteins and nucleic acids encoding them |
| AU2600800A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| AU5151100A (en) | 1999-05-19 | 2000-12-05 | Incyte Genomics, Inc. | Extracellular signaling molecules |
| AU3246100A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2004522402A (ja) * | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| CA2387711A1 (en) | 1999-08-27 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Novel g protein-coupled receptor protein and dna thereof |
| EP1230362A2 (de) | 1999-11-16 | 2002-08-14 | ZymoGenetics, Inc. | Menschliche zven proteine |
-
2001
- 2001-07-17 AT AT01951893T patent/ATE364698T1/de not_active IP Right Cessation
- 2001-07-17 AU AU2001272735A patent/AU2001272735A1/en not_active Abandoned
- 2001-07-17 WO PCT/JP2001/006162 patent/WO2002006483A1/ja not_active Ceased
- 2001-07-17 US US10/333,192 patent/US7045299B2/en not_active Expired - Fee Related
- 2001-07-17 DE DE60128916T patent/DE60128916T2/de not_active Expired - Lifetime
- 2001-07-17 EP EP01951893A patent/EP1302542B1/de not_active Expired - Lifetime
-
2005
- 2005-12-15 US US11/304,129 patent/US7419956B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1302542A4 (de) | 2005-05-11 |
| US20040077535A1 (en) | 2004-04-22 |
| DE60128916T2 (de) | 2007-09-20 |
| DE60128916D1 (de) | 2007-07-26 |
| US7419956B2 (en) | 2008-09-02 |
| EP1302542B1 (de) | 2007-06-13 |
| US20060088915A1 (en) | 2006-04-27 |
| WO2002006483A1 (fr) | 2002-01-24 |
| EP1302542A1 (de) | 2003-04-16 |
| US7045299B2 (en) | 2006-05-16 |
| AU2001272735A1 (en) | 2002-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE364698T1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| PL2157192T3 (pl) | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) | |
| DE60311272D1 (de) | Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten | |
| DE60311820D1 (de) | Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate | |
| ATE484494T1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| ATE316077T1 (de) | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| EP1978362A3 (de) | Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität | |
| ATE209684T1 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| DE60216457D1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| EA200501711A1 (ru) | Семейство секретируемых белков | |
| DE50212280D1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| DE60107888D1 (de) | Beta-Interferon zur Behandlung von Immunerkrankungen | |
| ATE491442T1 (de) | 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
| NO20034269L (no) | Anvendelse av forbindelser med den biologiske aktivitet til vaskoaktivt intestinalt peptid for behandlingen av kronisk obstruktiv pulmonalsykdom | |
| WO2002062944A2 (en) | Novel physiologically active peptide and use thereof | |
| DE10394363D2 (de) | Neue Chelidonin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen | |
| WO2002007676A3 (en) | Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) | |
| IL169256A (en) | Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE374260T1 (de) | Asthma-assoziiertes gen | |
| NO20052525D0 (no) | Spleisevariant av humant hypofyseveksthormon | |
| EA200501843A1 (ru) | Tnf-подобный секретируемый белок |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |